Highlight Therapeutics Announces Positive Preliminary Results from Phase IIb Study of BO-112 + Anti-PD1 in Confirmed Anti-PD1 Progressor Melanoma Patients at SITC

Highlight Therapeutics, Inc.announced positive preliminary results of a Phase II study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma whose disease had progressed on first-line anti-PD1-based therapy.